Multiobjective evolutionary optimization in antibody purification process design

To contribute towards designing more cost-efficient, robust and flexible downstream processes for the manufacture of monoclonal antibodies (mAbs), a framework consisting of an evolutionary multiobjective optimization algorithm (EMOA) linked to a biomanufacturing process economics model is presented. The EMOA is tuned to discover sequences of chromatographic purification steps and column sizing strategies that provide the best trade-off with respect to multiple objectives including cost of goods per gram (COG/g), robustness in COG/g, and impurity removal capabilities. Additional complexities accounted for by the framework include uncertainties and constraints. The framework is validated on industrially relevant case studies varying in upstream and downstream processing train ratios, annual demands, and impurity loads. Results obtained by the framework are presented using a range of visualization tools, and indicate that the performance impact of uncertainty is a function of both the level of uncertainty and the objective being optimized, and that uncertainty can cause otherwise optimal processes to become suboptimal. The optimal purification processes discovered outperform the industrial standard with, e.g. savings in COG/g of up to 10%. Guidelines are provided for choosing an optimal purification process as a function of the objectives being optimized and impurity levels present.

[1]  E Vásquez-Alvarez,et al.  Efficient MILP formulations for the optimal synthesis of chromatographic protein purification processes. , 2004, Journal of biotechnology.

[2]  David J Roush,et al.  Maximizing productivity of chromatography steps for purification of monoclonal antibodies , 2008, Biotechnology and bioengineering.

[3]  Suzanne S Farid,et al.  A computer‐aided approach to compare the production economics of fed‐batch and perfusion culture under uncertainty , 2006, Biotechnology and bioengineering.

[4]  Kalyanmoy Deb,et al.  A fast and elitist multiobjective genetic algorithm: NSGA-II , 2002, IEEE Trans. Evol. Comput..

[5]  Martin Smith,et al.  Decisional tool to assess current and future process robustness in an antibody purification facility , 2012, Biotechnology progress.

[6]  Peter J. Fleming,et al.  On the Performance Assessment and Comparison of Stochastic Multiobjective Optimizers , 1996, PPSN.

[7]  Suzanne S. Farid,et al.  Modelling biopharmaceutical manufacture: Design and implementation of SimBiopharma , 2007, Comput. Chem. Eng..

[8]  Marcus Degerman,et al.  A Model‐Based Approach to Determine the Design Space of Preparative Chromatography , 2009 .

[9]  Deborah K Follman,et al.  Factorial screening of antibody purification processes using three chromatography steps without protein A. , 2004, Journal of chromatography. A.

[10]  L C Eaton,et al.  Host cell contaminant protein assay development for recombinant biopharmaceuticals. , 1995, Journal of chromatography. A.

[11]  Anurag S. Rathore Resin screening to optimize chromatographic separations , 2001 .

[12]  J. Bonnerjea,et al.  Scale-up of monoclonal antibody purification processes. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  Adele P. Peskin,et al.  Optimization of large-scale chromatography for biotechnological applications , 1992 .

[14]  Jürgen Hubbuch,et al.  High Throughput Screening for the Design and Optimization of Chromatographic Processes: Automated Optimization of Chromatographic Phase Systems , 2009 .

[15]  Suzanne S. Farid,et al.  Efficient Discovery of Chromatography Equipment Sizing Strategies for Antibody Purification Processes Using Evolutionary Computing , 2012, PPSN.

[16]  Suzanne S. Farid,et al.  A multi-level meta-heuristic algorithm for the optimisation of antibody purification processes , 2012 .

[17]  Suzanne S. Farid,et al.  Dynamic Simulation Framework for Design of Lean Biopharmaceutical Manufacturing Operations , 2009 .

[18]  A. Hunter,et al.  Host cell proteins in biologics development: Identification, quantitation and risk assessment , 2009, Biotechnology and bioengineering.

[19]  Lazaros G. Papageorgiou,et al.  Optimal synthesis of chromatographic trains for downstream protein processing , 2011, Biotechnology progress.

[20]  J A Asenjo,et al.  Is there a rational method to purify proteins? From expert systems to proteomics , 2004, Journal of molecular recognition : JMR.

[21]  Sanchayita Ghose,et al.  Defining process design space for a hydrophobic interaction chromatography (HIC) purification step: Application of quality by design (QbD) principles , 2010, Biotechnology and bioengineering.

[22]  M.H.M. Eppink,et al.  Platform Technology for Developing Purification Processes , 2009 .

[23]  Manfred Kurz Regulatory considerations regarding quality aspects of monoclonal antibodies , 2007 .

[24]  J. Hintze,et al.  Violin plots : A box plot-density trace synergism , 1998 .

[25]  Gonzalo Guillén-Gosálbez,et al.  Hybrid simulation-optimization based approach for the optimal design of single-product biotechnological processes , 2012, Comput. Chem. Eng..

[26]  Abhinav A Shukla,et al.  Recent advances in large-scale production of monoclonal antibodies and related proteins. , 2010, Trends in biotechnology.

[27]  Kenneth Alan De Jong,et al.  An analysis of the behavior of a class of genetic adaptive systems. , 1975 .

[28]  P. Hinckley,et al.  Host cell protein clearance during protein a chromatography: Development of an improved column wash step , 2008, Biotechnology progress.

[29]  Jie Chen,et al.  The distinctive separation attributes of mixed-mode resins and their application in monoclonal antibody downstream purification process. , 2010, Journal of chromatography. A.

[30]  Suzanne S Farid,et al.  Decision‐Support Tool for Assessing Biomanufacturing Strategies under Uncertainty: Stainless Steel versus Disposable Equipment for Clinical Trial Material Preparation , 2008, Biotechnology progress.

[31]  M Vanderlaan,et al.  Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes , 2001, Biotechnology & genetic engineering reviews.

[32]  P A Marichal-Gallardo,et al.  State‐of‐the‐art in downstream processing of monoclonal antibodies: Process trends in design and validation , 2012, Biotechnology progress.

[33]  David W. Corne,et al.  Quantifying the Effects of Objective Space Dimension in Evolutionary Multiobjective Optimization , 2007, EMO.

[34]  Marcel Ottens,et al.  Design strategies for integrated protein purification processes: challenges, progress and outlook , 2008 .

[35]  Nigel J. Titchener-Hooker,et al.  A framework for assessing the solutions in chromatographic process design and operation for large-scale manufacture , 2006 .

[36]  Beckley K. Nfor,et al.  Model‐based rational strategy for chromatographic resin selection , 2011, Biotechnology progress.

[37]  Yuhong Zhou,et al.  Application of a Decision‐Support Tool to Assess Pooling Strategies in Perfusion Culture Processes under Uncertainty , 2008, Biotechnology progress.

[38]  Seppo Ylä-Herttuala,et al.  Challenges in monoclonal antibody-based therapies , 2009, Annals of medicine.

[39]  Melanie Mitchell,et al.  An introduction to genetic algorithms , 1996 .